DailyIQ
|
Sector:HealthcareAll sectors
Last updated 7 minutes ago

ROIV·Roivant Sciences Ltd.

$.
-. (-.%)
After Hours
High
$37.79
Open
$36.91
Market Cap
25.87B
52W High
$37.00
Low
$35.27
P. Close
$35.98
P/E
-
52W Low
$10.90
Fwd P/E
-23.07
DailyIQ Est.
$41.39
Technical Score (1D)
82
BUY
News Sentiment
67
BULLISH
Genevant, a Roivant unit, secured a global settlement with Moderna valued at up to $2.25 billion, with a $950 million upfront payment due July 8, of which Arbutus expects roughly $179 million after costs. The influx of settlement proceeds will strengthen Roivant’s balance sheet and could enable the company to return capital to shareholders later this year, improving cash flow and potentially supporting future investment in its Vants pipeline. This financial boost comes as analysts project significant revenue growth from upcoming product launches in oncology and rare disease, with regulatory approvals poised to accelerate sales. Argus Research’s recent upgrade of the target price to $37 reflects confidence in this earnings outlook and margin expansion, underscoring a bullish view for the next 1–10 trading days. However, insider sales totaling $56 million and a $49 million sale in the past months raise questions about sentiment, though they represent a small fraction of the float and may not signal a fundamental shift. The company’s Vants model, which accelerates development across multiple therapeutic areas, has already driven a share price surge to $35 and a $25 billion market cap, but scaling and regulatory hurdles remain a risk. Traders should watch for the July 8 payment confirmation and any subsequent capital return decision, as this will clarify the timing of cash availability. Monitoring regulatory milestones for the oncology and rare disease candidates will be key, as approvals could trigger the projected revenue expansion. Additionally, any further insider activity or earnings guidance will help gauge whether the recent financial gains translate into sustained operational momentum.
Earnings Summary
Roivant Sciences (ROIV) is a clinical‑stage biopharmaceutical company focused on developing and commercializing innovative medicines and technologies, with a pipeline that includes monoclonal antibodies, small‑molecule inhibitors, and inhaled therapies for autoimmune and pulmonary conditions. Operating in the biotechnology sector, the company leverages advanced delivery platforms such as lipid nanoparticles and ligand conjugates to enhance drug development. In Q1 2025, ROIV reported a net loss per share of $0.21829 versus an estimate of $0.16333, and generated $7.57 million in revenue, though no revenue estimate was provided for that quarter; the company’s earnings guidance for Q2 2025 and Q1 2026 remains pending, leaving a gap in recent actuals that precludes a full comparison of the last two quarters to the prior two periods. Not enough information is available to assess a historical growth streak or to identify consistent patterns of beats or misses across multiple periods. Recent news highlights a presentation by CEO Matthew Gline at the Bernstein 42nd Annual Strategic Decisions Conference, where he outlined pipeline progress, upcoming clinical milestones for several assets, and a portfolio‑optimization strategy that could streamline cash flow and valuation; analysts have raised price targets following positive Phase 2 data for brepocitinib, and the company’s strong $4.5 billion cash position provides a cushion for pursuing these milestones. Investors should watch for the announced timelines for the X therapy phase, any guidance on asset valuations, and potential divestitures or new pipeline additions, as these developments will clarify the company’s near‑term cash burn and potential revenue streams. Investors should watch for the next earnings call for updated financial metrics and any clarification on the pipeline roadmap, which will be critical for assessing ROIV’s trajectory in the coming weeks.

EPS

EstBeatMiss
$-0.38$-0.32$-0.26$-0.20$-0.13Q1'25Q2'25
QtrEstActual+/−
Q2'25$-0.36 - -
Q1'25$-0.16$-0.22-33.6%

Revenue

EstBeatMiss
$2M$3M$5M$7M$8MQ1'25Q2'25
QtrEstActual+/−
Q2'25$2M - -
Q1'25 - $8M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

ROIV Stock Snapshot

ROIV is currently trading at $35.91, giving Roivant Sciences Ltd. a market cap of 25.87B. Today's range spans $35.27–$37.79, with shares opening at $36.91 and moving down $0.07 (0.2%) from the prior close. DailyIQ's technical score sits at 82/100 (BUY) with a news sentiment reading of 67/100.

Over the past year ROIV has traded between $10.90 and $37.00 - the current price is +229.4% off the 52-week low and -2.9% from the high. 21 analysts cover the stock with a Buy consensus and a mean 12-month target of $39.38 (range $31.50–$49.00), implying upside of +9.7%.

If you're looking for bullish momentum in Healthcare, ROIV is putting up the numbers: 82/100 technical score, BUY signal, bullish sentiment at 67/100. Price: $35.91 (near 52-week highs). The 25.87B market cap keeps it in play for institutional position sizes, and the $10.90–$37.00 annual range shows this stock can make real moves when it gets directional conviction behind it.

What makes ROIV's BUY setup (82/100) particularly actionable at 25.87B in Healthcare capitalization is the scale-to-move ratio: large enough to feature on institutional mandates but not so large that the percentage upside is already compressed by index inertia. At $35.91 (near 52-week highs in $10.90–$37.00), with sentiment running bullish at 67/100, the setup rewards conviction-sized positioning more than it does speculative small bets.